1. Home
  2. RGEN vs MIRM Comparison

RGEN vs MIRM Comparison

Compare RGEN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$186.76

Market Cap

10.0B

Sector

Health Care

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$91.24

Market Cap

7.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGEN
MIRM
Founded
1981
2018
Country
United States
United States
Employees
2000
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0B
7.2B
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
RGEN
MIRM
Price
$186.76
$91.24
Analyst Decision
Buy
Strong Buy
Analyst Count
12
13
Target Price
$167.67
$119.85
AVG Volume (30 Days)
853.9K
464.4K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
286.96
74.59
EPS
0.24
N/A
Revenue
$141,236,000.00
$19,138,000.00
Revenue This Year
$14.30
$26.22
Revenue Next Year
$14.52
$22.04
P/E Ratio
$752.96
N/A
Revenue Growth
35.10
N/A
52 Week Low
$100.99
$63.23
52 Week High
$188.73
$130.00

Technical Indicators

Market Signals
Indicator
RGEN
MIRM
Relative Strength Index (RSI) 62.97 37.91
Support Level $158.15 $88.08
Resistance Level $188.73 $98.03
Average True Range (ATR) 5.68 3.90
MACD 0.33 -0.37
Stochastic Oscillator 94.17 10.13

Price Performance

Historical Comparison
RGEN
MIRM

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Share on Social Networks: